2022. ORM 1 as a biomarker of increased vascular invasion and decreased sorafenib sensitivity in hepatocellular carcinoma. Biomolecules and Biomedicine. 22, 6 (Oct. 2022), 949–958. DOI:https://doi.org/10.17305/bjbms.2022.7268.